CD8A and melanoma: For instance, in melanoma, the PI3K/Akt, MyD88, and IKK pathways could be involved in IL-36β-mediated mTORC1 activation, promoting CD8+ T cell activation and inducing antitumor immune responses in vitro and in vivo [180].